
Invivyd Inc (IVVD) Stock Forecast & Price Target
Invivyd Inc (IVVD) Analyst Ratings
Bulls say
Invivyd Inc. has successfully closed a $57.5 million public offering, significantly enhancing its financial stability and supporting the development of its key antibody candidates, ADG20 and VYD222, aimed at combating viral diseases, including COVID-19. The results from the Phase 1/2 ‘extreme-dose’ safety trial indicate high confidence in the long-term use of VYD2311, revealing no serious adverse events and demonstrating a favorable safety profile compared to existing COVID vaccines. Additionally, VYD2311's strong manufacturing efficiency and projected robust supply capability position the company well to meet anticipated market demand, further solidifying its strategic outlook.
Bears say
Invivyd Inc has recently experienced a significant downward adjustment in expectations regarding its market share, particularly for PEMGARDA in the immunocompromised patients market, leading to a price target reduction from $3.00 to $1.00 due to capital raise-related dilution. The company’s strategic focus on developing engineered antibodies aims to enhance human immune function; however, the limitations of existing vaccines, such as waning antibody responses and public hesitancy, continue to present challenges. Additionally, while the total addressable market for COVID vaccine revenue is projected at approximately $4 billion, the prevailing concerns around efficacy and the company's competitive position dampen the outlook for its stock.
This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.
Invivyd Inc (IVVD) Analyst Forecast & Price Prediction
Start investing in Invivyd Inc (IVVD)
Order type
Buy in
Order amount
Est. shares
0 shares